PHENOBARBITAL SODIUM INJECTION, USP 30 MG
PHENOBARBITAL SODIUM : 30 MG · DIN 02304082 · SANDOZ CANADA INCORPORATED
Health Canada status: MARKETED
What is PHENOBARBITAL SODIUM INJECTION, USP?
PHENOBARBITAL SODIUM INJECTION, USP 30 MG contains PHENOBARBITAL SODIUM : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 02304082, held by SANDOZ CANADA INCORPORATED, supplied as SOLUTION for INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 29-Feb-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PHENOBARBITAL SODIUM INJECTION, USP used for?
Control of generalized tonic-clonic and complex partial seizures. Parenteral management of status epilepticus or acute seizure episodes.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02304082 |
|---|---|
| Brand name | PHENOBARBITAL SODIUM INJECTION, USP |
| Generic / active ingredient | PHENOBARBITAL SODIUM : 30 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 30 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS ; INTRAMUSCULAR |
| Schedule | CONTROLLED DRUGS (CDSA IV) |
| ATC code | N03AA02 PHENOBARBITAL |
| AHFS class | 28:12.04 ; 28:24.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 29-Feb-2008 |
| Original market date | 2008-02-29 00:00:00 |
How is it administered?
Deep IM or slow IV injection. Adults: 100-320 mg IV for anticonvulsant; up to 600 mg/day. Status epilepticus: 20 mg/kg IV. Children: 1-6 mg/kg/day maintenance. Max 2 g daily.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15°C and 25°C. Protect from freezing. Protect from light. Do not use if precipitate present.
How is it supplied?
Boxes of 10 ampoules of 1 mL each.
Contraindications
Hypersensitivity to barbiturates; porphyria; severe respiratory depression; renal/hepatic impairment; sleep apnea; suicidal potential; alcoholism; drug dependence; uncontrolled pain; newborns.
Warnings and precautions
Risk of suicidal ideation; serious skin reactions (SJS/TEN); potential for dependence/withdrawal; respiratory depression; avoid extravasation; risk of decreased bone mineral density.
What can be used instead?
Other Canadian products sharing ATC code N03AA02 PHENOBARBITAL. 11 of 30 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP PHENOBARBITAL | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02557819 |
| JAMP PHENOBARBITAL | 15 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02557789 |
| JAMP PHENOBARBITAL | 30 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02557797 |
| JAMP PHENOBARBITAL | 60 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02557800 |
| PHENOBARB | 100 MG | TABLET | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 00178829 |
| PHENOBARB | 15 MG | TABLET | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 00178799 |
| PHENOBARB | 30 MG | TABLET | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 00178802 |
| PHENOBARB | 60 MG | TABLET | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 00178810 |
| PHENOBARB ELIXIR | 5 MG | SOLUTION | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 00645575 |
| PHENOBARBITAL SODIUM INJECTION, USP | 120 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02304090 |
Who else supplies PHENOBARBITAL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PHENOBARBITAL appears in 41 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.